MRC1 and colorectal carcinoma: MMR-deficient and MSI-H CRC patients are often good candidates for immune checkpoint inhibitor therapy (ICI) as this phenotype is a biomarker for chemotherapeutic resistance to drugs like 5-fluorouracil (5-FU), platinum, and methylating agents [14,15,16].